Thus, the favorable binding affinities observed for CD180, F10, HIST1H2BJ, and MBNL3 with CDP323 and teriflunomide suggest that these proteins could serve as potential therapeutic targets for MS treatment. The gene discussed is MBNL3; the disease is myeloid sarcoma.